bluuebunny/crossref_metadata_2025_split huggingface dataset:
On the origin of mixed morphology supernova remnants: linking their properties to the evolution of a red supergiant progenitor star
Authors: Chiotellis Alexandros , Zapartas Emmanouil , Meyer Dominique M -A 
Published: May 2024

ABSTRACT
Mixed-morphology supernova remnants (MMSNRs) are characterized by a shell-like morphology in the radio and centrally peaked thermal emission in the X-ray band. The nature of this peculiar class of supernova remnants (SNRs) remains a controversial issue. In this work, by pairing the predictions of stellar evolution theory with two-dimensional hydrodynamic simulations, we show that the mixed morphology properties of an SNR can arise by the interaction of the SNR with the circumstellar medium shaped by a red supergiant progenitor star, embedded in a dense environment. As a study case, we model the circumstellar medium formation and the subsequent interaction of the SNR with it of a $15~\rm {\rm M}_{\odot }$ progenitor star. The reflected shock, formed by the collision of the SNR with the density walls of the surrounding circumstellar cavity, accumulates and re-shocks the supernova ejecta at the centre of the remnant, increasing its temperature so that the gas becomes X-ray bright. Such a formation mechanism may naturally explain the nature of MMSNRs resulted from Type II supernovae without the demand of additional physical mechanisms and/or ambient medium inhomogeneities. We discuss alternative evolutionary paths that potentially could be ascribed for the MMSNR formation within the framework of the reflected shock model.
Radiomics-based prediction of local control in patients with brain metastases following postoperative stereotactic radiotherapy
Authors: Buchner Josef A , Kofler Florian , Mayinger Michael , Christ Sebastian M , Brunner Thomas B , Wittig Andrea , Menze Bjoern , Zimmer Claus , Meyer Bernhard , Guckenberger Matthias , Andratschke Nicolaus , El Shafie Rami A , Debus Jürgen , Rogers Susanne , Riesterer Oliver , Schulze Katrin , Feldmann Horst J , Blanck Oliver , Zamboglou Constantinos , Ferentinos Konstantinos , Bilger-Zähringer Angelika , Grosu Anca L , Wolff Robert , Piraud Marie , Eitz Kerstin A , Combs Stephanie E , Bernhardt Denise , Rueckert Daniel , Wiestler Benedikt , Peeken Jan C 
Published: May 2024

Abstract

Background
Surgical resection is the standard of care for patients with large or symptomatic brain metastases (BMs). Despite improved local control after adjuvant stereotactic radiotherapy, the risk of local failure (LF) persists. Therefore, we aimed to develop and externally validate a pre-therapeutic radiomics-based prediction tool to identify patients at high LF risk.

Methods
Data were collected from A Multicenter Analysis of Stereotactic Radiotherapy to the Resection Cavity of BMs (AURORA) retrospective study (training cohort: 253 patients from 2 centers; external test cohort: 99 patients from 5 centers). Radiomic features were extracted from the contrast-enhancing BM (T1-CE MRI sequence) and the surrounding edema (T2-FLAIR sequence). Different combinations of radiomic and clinical features were compared. The final models were trained on the entire training cohort with the best parameter set previously determined by internal 5-fold cross-validation and tested on the external test set.

Results
The best performance in the external test was achieved by an elastic net regression model trained with a combination of radiomic and clinical features with a concordance index (CI) of 0.77, outperforming any clinical model (best CI: 0.70). The model effectively stratified patients by LF risk in a Kaplan–Meier analysis (P &lt; .001) and demonstrated an incremental net clinical benefit. At 24 months, we found LF in 9% and 74% of the low and high-risk groups, respectively.

Conclusions
A combination of clinical and radiomic features predicted freedom from LF better than any clinical feature set alone. Patients at high risk for LF may benefit from stricter follow-up routines or intensified therapy.
Dietary Magnesium Intake in Relation to Depression in Adults: A GRADE-Assessed Systematic Review and Dose–Response Meta-analysis of Epidemiologic Studies
Authors: Hajhashemy Zahra , Shirani Fatemeh , Askari Gholamreza 
Published: May 2024

Abstract

Context
The relation of magnesium (Mg) intake with depression was previously investigated by meta-analyses. However, due to limited data, a dose–response analysis was not performed.

Objective
Considering the recently published articles, a systematic review and dose–response meta-analysis was conducted to summarize the relation of dietary Mg intake with depression in adults.

Data Sources
Medline (PubMed), ISI Web of Science, Scopus, and Google Scholar were comprehensively searched up to August 2023.

Data Extraction
Observational studies that reported the relation of dietary Mg intake and depression in adults were included and their data were extracted.

Data Analysis
A total of 63 214 participants from 10 cross-sectional and 3 cohort studies were included in the current study. Pooling 15 effect sizes from 12 studies (including 50 275 participants) revealed that individuals with the highest Mg intake had a 34% lower risk of depression, compared with those with the lowest Mg intake (RR: 0.66; 95% CI: 0.57, 0.78). Moreover, the linear dose–response analysis revealed that each 100-mg/d increment in Mg intake was associated with a 7% reduced risk of depression (RR: 0.93; 95% CI: 0.90, 0.96). Additionally, based on nonlinear dose–response analysis, increasing Mg intake from 170 to 370 mg/d was associated with a reduced risk of depression. Analyses were also conducted on 9 studies (49 558 participants) with representative populations, and similar results were found in the meta-analysis (RR: 0.71; 95% CI: 0.61, 0.83) and linear (RR: 0.93; 95% CI: 0.90, 0.96) and nonlinear dose–response analysis.

Conclusion
The current study shows an inverse dose–dependent association between dietary Mg intakes and risk of depression in both a general and representative population of adults in a dose–response manner.

Systematic Review Registration
PROSPERO registration no. CRD42024506570.
Olaparib for childhood tumors harboring defects in DNA damage repair genes: arm H of the NCI-COG Pediatric MATCH trial
Authors: Glade Bender Julia L , Pinkney Kerice , Williams Paul M , Roy-Chowdhuri Sinchita , Patton David R , Coffey Brent D , Reid Joel M , Piao Jin , Saguilig Lauren , Alonzo Todd A , Berg Stacey L , Ramirez Nilsa C , Fox Elizabeth , Weigel Brenda J , Hawkins Douglas S , Mooney Margaret M , Takebe Naoko , Tricoli James V , Janeway Katherine A , Seibel Nita L , Parsons Donald W 
Published: May 2024

Abstract

Background
The National Cancer Institute-Children’s Oncology Group Pediatric Molecular Analysis for Therapy Choice (MATCH) precision oncology platform trial enrolled children aged 1-21 years with treatment-refractory solid tumors and predefined actionable genetic alterations. Patients with tumors harboring alterations in DNA damage repair (DDR) genes were assigned to receive olaparib.

Methods
Tumor and blood samples were submitted for centralized molecular testing. Tumor and germline sequencing were conducted in parallel. Olaparib was given twice daily for 28-day cycles starting at a dose 30% lower than the adult recommended phase 2 dose (RP2D). The primary endpoint was the objective response.

Results
Eighteen patients matched (1.5% of those screened) based on the presence of a deleterious gene alteration in BRCA1/2, RAD51C/D, or ATM detected by tumor sequencing without germline subtraction or analysis of loss of heterozygosity (LOH). Eleven (61%) harbored a germline mutation, with only one exhibiting LOH. Six patients enrolled and received the olaparib starting dose of 135 mg/m2/dose. Two participants were fully evaluable; 4 were inevaluable because &lt;85% of the prescribed dose was administered during cycle 1. There were no dose-limiting toxicities or responses. Minimal hematologic toxicity was observed.

Conclusion
Most DDR gene alterations detected in Pediatric MATCH were germline, monoallelic, and unlikely to confer homologous recombination deficiency predicting sensitivity to olaparib monotherapy. The study closed due to poor accrual.

ClinicalTrials.gov Identifier
NCT03233204. IRB approved: initial July 24, 2017.
Deep learning-based multi-modal data integration enhancing breast cancer disease-free survival prediction
Authors: Wang Zehua , Lin Ruichong , Li Yanchun , Zeng Jin , Chen Yongjian , Ouyang Wenhao , Li Han , Jia Xueyan , Lai Zijia , Yu Yunfang , Yao Herui , Su Weifeng 
Published: May 2024

Abstract

Background
The prognosis of breast cancer is often unfavorable, emphasizing the need for early metastasis risk detection and accurate treatment predictions. This study aimed to develop a novel multi-modal deep learning model using preoperative data to predict disease-free survival (DFS).

Methods
We retrospectively collected pathology imaging, molecular and clinical data from The Cancer Genome Atlas and one independent institution in China. We developed a novel Deep Learning Clinical Medicine Based Pathological Gene Multi-modal (DeepClinMed-PGM) model for DFS prediction, integrating clinicopathological data with molecular insights. The patients included the training cohort (n = 741), internal validation cohort (n = 184), and external testing cohort (n = 95).

Result
Integrating multi-modal data into the DeepClinMed-PGM model significantly improved area under the receiver operating characteristic curve (AUC) values. In the training cohort, AUC values for 1-, 3-, and 5-year DFS predictions increased to 0.979, 0.957, and 0.871, while in the external testing cohort, the values reached 0.851, 0.878, and 0.938 for 1-, 2-, and 3-year DFS predictions, respectively. The DeepClinMed-PGM's robust discriminative capabilities were consistently evident across various cohorts, including the training cohort [hazard ratio (HR) 0.027, 95% confidence interval (CI) 0.0016–0.046, P &lt; 0.0001], the internal validation cohort (HR 0.117, 95% CI 0.041–0.334, P &lt; 0.0001), and the external cohort (HR 0.061, 95% CI 0.017–0.218, P &lt; 0.0001). Additionally, the DeepClinMed-PGM model demonstrated C-index values of 0.925, 0.823, and 0.864 within the three cohorts, respectively.

Conclusion
This study introduces an approach to breast cancer prognosis, integrating imaging and molecular and clinical data for enhanced predictive accuracy, offering promise for personalized treatment strategies.
Reinterpretation of the post-26 ka Taupō Rhyolitic Magmatic System (New Zealand) as Deep and Vertically Extensive Based on Isotope Thermometry and Measured and Modeled Zircon Destinies
Authors: Bindeman Ilya N 
Published: May 2024

Abstract
Taupō volcanic zone, the site of the 26 ka Oruanui supereruption, produced ~70 km3 of new rhyolites since 11 ka, culminating in 50 km3 Taupō eruption 1.8 ka. Major phenocrysts decrease from 4 to 1 vol%, and Oruanui and post-Oruanui ignimbrites all have identical high-δ18Omelt values of 7.39 ± 0.1‰ and lack low-δ18O values despite overlapping calderas. The Δ’17O values are −0.07‰, lower than the mantle and indicate source contamination of high-δ18O, low-Δ’17O metasediments, and limited interaction with high-Δ’17O hydrothermally altered crust. Previously published U-Th-Pb zircon ages demonstrate their diversity spanning 104–105 years for each unit. Zircon crystal size distribution shows a decrease in abundance and the mean size, and some units lack small (&lt;~10 um) zircons suggesting that zircons were both growing and dissolving in the coexisting magma generation areas. Isotope thermometry indicates heating of the system from ~812 ± 35°C to 874 ± 36°C past zircon saturation in 1.8 ka eruption. We advocate that a deep vertically continuous and laterally discontinuous silicic magma system at the base of the Taupō rift, rather than a shallow batholith or an evolving mush, drives volcanism at Taupō. To explain the post-Oruanui magma production, rift-base silicic magma origin and moderate (~2 km3/1000 years) rhyodacitic magma flux from a growing and heating liquid magma body creates a sufficient solution for the most recent magmatism.
Unraveling the Prefrontal Cortex-Basolateral Amygdala Pathway’s Role on Schizophrenia’s Cognitive Impairments: A Multimodal Study in Patients and Mouse Models
Authors: Liang Jiaquan , Chen Lei , Li Yongbiao , Chen Yuewen , Yuan Lin , Qiu Yue , Ma Shuangshuang , Fan Fangcheng , Cheng Yong 
Published: May 2024

Abstract

Background and Hypothesis
This study investigated the role of the medial prefrontal cortex (mPFC)-basolateral amygdala (BLA) pathway in schizophrenia (SCZ)-related cognitive impairments using various techniques.

Study Design
This study utilized clinical scales, magnetic resonance imaging, single-cell RNA sequencing, and optogenetics to investigate the mPFC-BLA pathway in SCZ patients. In the mouse model, 6-week-old methylazoxymethanol acetate-induced mice demonstrated significant cognitive deficits, which were addressed through stereotaxic injections of an adeno-associated viral vector to unveil the neural connection between the mPFC and BLA.

Study Results
Significant disparities in brain volume and neural activity, particularly in the dorsolateral prefrontal cortex (DLPFC) and BLA regions, were found between SCZ patients and healthy controls. Additionally, we observed correlations indicating that reduced volumes of the DLPFC and BLA were associated with lower cognitive function scores. Activation of the mPFC-BLA pathway notably improved cognitive performance in the SCZ model mice, with the targeting of excitatory or inhibitory neurons alone failing to replicate this effect. Single-cell transcriptomic profiling revealed gene expression differences in excitatory and inhibitory neurons in the BLA of SCZ model mice. Notably, genes differentially expressed in the BLA of these model mice were also found in the blood exosomes of SCZ patients.

Conclusions
Our research provides a comprehensive understanding of the role of the PFC-BLA pathway in SCZ, underscoring its significance in cognitive impairment and offering novel diagnostic and therapeutic avenues. Additionally, our research highlights the potential of blood exosomal mRNAs as noninvasive biomarkers for SCZ diagnosis, underscoring the clinical feasibility and utility of this method.
Csn-miR156d targeting CsSPL1 plays an important role in flowering and anthocyanin metabolism of tea plant
Authors: Lin Qingqing , Li Hui , He Hu , Wang Pu , Wang Mingle , Zhao Hua , Wang Yu , Ni Dejiang , Fang Yanni , Guo Fei 
Published: May 2024

Abstract
miR156 play important roles in regulation of plant growth and development, secondary metabolite synthesis and other biological processes by targeting the SQUAMOSA promoter binding protein-like (SPL) family. Our previous sequencing data analysis suggested that Csn-miR156d may regulate flowering and anthocyanin accumulation by cleavage and degradation of the expression of the SPL in tea plant, but it remains to be elucidated. In this study, 5′RLM-RACE experiment, tobacco transient transformation, qRT-PCR and antisense oligonucleotide (asODN) were used to verify that CsSPL1 is the target gene of Csn-miR156d. Stable transformation of Arabidopsis revealed that Csn-miR156d could delay flowering by negatively regulating the transcript levels of FT, AP1, FUL and SOC1, while overexpression of CsSPL1 showed an opposite effect. Additionally, overexpression of Csn-miR156d in Arabidopsis could enhance the transcription of the anthocyanin biosynthesis-related structural genes DFR, ANS, F3H, UGT78D2 and LDOX, as well as regulatory genes PAP1, MYB113, GL3, MYB11 and MYB12, leading to anthocyanin accumulation. Moreover, asODN experiment revealed that Csn-miR156d could increase the anthocyanin content in tea plant. These results suggest that Csn-miR156d regulates flowering and anthocyanin accumulation in tea plant by suppressing the expression of CsSPL1. Our study provides new insights into the development and anthocyanin accumulation in tea plant and lays a theoretical foundation for further research on the molecular mechanism of miRNAs in regulating tea plant growth and secondary metabolism.
A Narrative Review of NICU Implementation of Evidence-Based Early Relational Health Interventions
Authors: Darilek Umber , Finley Erin , McGrath Jacqueline 
Published: May 2024

Background:
Early relational health (ERH) interventions in the neonatal intensive care unit (NICU) buffer infants from toxic stress effects. Implementation science (IS) can guide successful uptake of evidence-based practice (EBP) ERH interventions. It is unknown if implementors of ERH interventions currently use the resources of IS to improve implementation.

Purpose:
A narrative review of recent literature on implementation of ERH EBPs was completed to understand (a) which ERH interventions are currently being implemented in NICUs globally, (b) whether clinical implementors of ERH interventions have adopted the resources of IS, (c) existence of implementation gaps, and (d) implementation outcomes of ERH interventions in contemporary literature.

Data Sources:
Scopus, PubMed, and CINHAL were searched for original research regarding implementation of dyadic ERH interventions using key words related to IS and ERH.

Study Selection:
For inclusion, ERH EBPs had to have been implemented exclusively in NICU settings, contained data addressing an IS domain, printed in English within the last 5 years. Twenty-four studies met inclusion criteria.

Data Extraction:
Studies were distilled for intervention, IS domains addressed, location, aims, design, sample, and outcomes.

Results:
Eleven ERH interventions were described in the literature. Few studies utilized the resources of IS, indicating variable degrees of success in implementation. Discussions of implementation cost were notably missing

Implications for Practice and Research:
Implementors of ERH interventions appear to be largely unfamiliar with IS resources. More work is needed to reach clinicians with the tools and resources of IS to improve implementation outcomes.
Reducing Noise in the NICU
Authors: Gennattasio Annmarie , Carter Brigit , Maffei Diana , Turner Barbara , Weinberger Barry , Boyar Vitaliya 
Published: May 2024

Background:
In the neonatal intensive care unit (NICU), elevated noise negatively impacts the neurodevelopmental environment, interrupts sleep, and can affect brain development in neonates. The American Academy of Pediatrics recommends that noise levels in the NICU should not exceed 45 dB.

Purpose:
The project aims were to: (1) decrease average noise level by 10% from baseline and (2) decrease exposure to severe noise (>65 dB) to <5% of the time.

Methods:
This quality improvement project was conducted during 2021-2022 as a pre/post observational design in a Level IV NICU in New York City. We monitored sound levels for 20-24 h, 5 d/wk. Quality improvement interventions included: novel approaches to staff education, visual cues for when noise thresholds were exceeded, parent education, including access to personal decibel meters, technical improvements to vital sign monitors and entry doors, and defined quiet times (HUSH) for 2 h each 12-hour shift.

Results:
Education efforts and technical improvements successfully reduced median noise levels within the stepdown unit (P < .001), though not in the acute care NICU. In contrast, the implementation of 2-hour periods of enforced “quiet time” every 12 h effectively reduced both median noise levels and the incidence of severe noise (>65 dB) in both locations.

Implications for practice and research:
The HUSH strategy may be a sustainable way to decrease noise in the NICU. Future projects should prioritize education and dedicated quiet times to align with recommended standards, while research should explore the long-term developmental impacts of excessive noise levels on neonatal growth.
Gene therapy using retrovirally transduced human chondrocytes expressing TGF-β1: a systematic review of early results are not promising!
Authors: Kumar Vishal , Patel Sandeep , Baburaj Vishnu , Neradi Deepak , Kaushal Aditya 
Published: May 2024

Background:
Gene therapy is a promising ortho-biologic product for Osteoarthritis (OA) knee with some level 2 and 3 studies. There is a need to evaluate the safety and efficacy of this therapy with a systematic review by pooling the data from the limited clinical trials to give an early idea of the product.

Methods:
Pubmed, Embase, and Scopus were searched for articles related to gene therapy use in human trials for osteoarthritis using mesh terms. After screening, seven RCTs were included in this review. Clinical outcomes with IKDC scores, VAS, and adverse effects were analyzed.

Results:
All studies reported significant improvement in functional outcomes measured with IKDC scores. VAS scores showed mixed results. WOMAC scores and WORMS scoring reported no significant difference between the treatment and placebo groups, but the progression of OA was decreased in the treatment group.

Conclusion:
Gene therapy could potentially improve knee-related functional outcomes and alleviate pain. While some studies indicate positive effects on knee morphology, further research is needed in this regard. Adverse events, though generally manageable, require ongoing vigilance. Gene therapy holds the potential to enhance the quality of life for individuals with osteoarthritis knee.
Pan-cancer single-cell landscape of drug-metabolizing enzyme genes
Authors: Mao Wei , Zhou Tao , Zhang Feng , Qian Maoxiang , Xie Jianqiang , Li Zhengyan , Shu Yang , Li Yuan , Xu Heng 
Published: May 2024

Objective
Varied expression of drug-metabolizing enzymes (DME) genes dictates the intensity and duration of drug response in cancer treatment. This study aimed to investigate the transcriptional profile of DMEs in tumor microenvironment (TME) at single-cell level and their impact on individual responses to anticancer therapy.

Methods
Over 1.3 million cells from 481 normal/tumor samples across 9 solid cancer types were integrated to profile changes in the expression of DME genes. A ridge regression model based on the PRISM database was constructed to predict the influence of DME gene expression on drug sensitivity.

Results
Distinct expression patterns of DME genes were revealed at single-cell resolution across different cancer types. Several DME genes were highly enriched in epithelial cells (e.g. GPX2, TST and CYP3A5) or different TME components (e.g. CYP4F3 in monocytes). Particularly, GPX2 and TST were differentially expressed in epithelial cells from tumor samples compared to those from normal samples. Utilizing the PRISM database, we found that elevated expression of GPX2, CYP3A5 and reduced expression of TST was linked to enhanced sensitivity of particular chemo-drugs (e.g. gemcitabine, daunorubicin, dasatinib, vincristine, paclitaxel and oxaliplatin).

Conclusion
Our findings underscore the varied expression pattern of DME genes in cancer cells and TME components, highlighting their potential as biomarkers for selecting appropriate chemotherapy agents.